Recently Featured

SK bioscience to lead Gates Foundation-funded ROTOR project

August 10, 2026
SK bioscience is set to lead the Gates Foundation-funded ROTOR project, an AI-based platform aimed at reducing uncertainty in vaccine-development decisions. This initiative underscores the growing importance of artificial intelligence in streamlining vaccine research and development, particularly in a landscape that demands rapid responses to emerging health threats. The ROTOR project is designed to leverage…

UK Guidance on Best Practices for Labelling and Packaging of Medicines Released

August 10, 2026
The UK government has released new guidance outlining best practices for the labelling and packaging of medicines, clarifying the legal framework established under UK legislation. This comprehensive document serves as a crucial resource for pharmaceutical professionals involved in regulatory compliance, quality assurance, and product development. It emphasizes the importance of accurate and clear labelling, which…

European Commission Approves Novartis’ Itvisma to Treat SMA

August 10, 2026
The European Commission has granted approval for Novartis’ Itvisma, marking a significant advancement in the treatment landscape for spinal muscular atrophy (SMA). This therapy is specifically indicated for children aged two years and older, as well as teenagers and adults diagnosed with 5q SMA who possess a bi-allelic mutation in the SMN1 gene. This approval…

Medicare Proposes Significant Cuts to 340B Drug Payments for Hospitals

August 9, 2026
Medicare is set to reduce payments to hospitals for drugs acquired through the 340B drug discount program by over 33% starting next year, following findings that some patients are paying more for these drugs than the hospitals themselves. This proposal, unveiled in a recent rule on hospital outpatient payments, suggests that Medicare would reimburse hospitals…

Ongoing Cases